» Articles » PMID: 35315224

Colorectal Cancer Screening Preferences Among Physicians and Individuals at Average Risk: A Discrete Choice Experiment

Overview
Journal Cancer Med
Specialty Oncology
Date 2022 Mar 22
PMID 35315224
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Guidelines include several options for average-risk colorectal cancer (CRC) screening that vary in aspects such as invasiveness, recommended frequency, and precision. Thus, patient and provider preferences can help identify an appropriate screening strategy. This study elicited CRC screening preferences of physicians and individuals at average risk for CRC (IAR).

Methods: IAR aged 45-75 years and licensed physicians (primary care or gastroenterology) completed an online discrete choice experiment (DCE). Participants were recruited from representative access panels in the US. Within the DCE, participants traded off preferences between screening type, screening frequency, true-positive, true-negative, and adenoma true positive (physicians only). A mixed logit model was used to obtain predicted choice probabilities for colonoscopy, multi-target stool DNA (mt-sDNA), fecal immunochemical test (FIT), and methylated septin 9 (mSEPT9) blood test.

Results: Preferences of IAR and physicians were affected by screening precision and screening type. IAR also valued more regular screening. Physicians preferred colonoscopy (96.8%) over mt-sDNA (2.8%; p < 0.001), FIT (0.3%; p < 0.001) and mSEPT9 blood test (0.1%; p < 0.01). IAR preferred mt-sDNA (38.8%) over colonoscopy (32.5%; p < 0.001), FIT (19.2%; p < 0.001), and mSEPT9 blood test (9.4%; p < 0.001). IAR naïve to screening preferred non-invasive screening (p < 0.001), while the opposite was found for those who previously underwent colonoscopy or sigmoidoscopy.

Conclusions: While physicians overwhelmingly preferred colonoscopy, preferences of IAR were heterogenous, with mt-sDNA being most frequently preferred on average. Offering choices in addition to colonoscopy could improve CRC screening uptake among IAR. This study used a discrete choice experiment in the US to elicit preferences of physicians and individuals at average risk for colorectal cancer screening modalities and their characteristics.

Citing Articles

Colorectal Cancer Screening Receipt Does Not Differ by 10-Year Mortality Risk Among Older Adults.

Liu P, Singal A, Murphy C Am J Gastroenterol. 2023; 119(2):353-363.

PMID: 37782288 PMC: 10872814. DOI: 10.14309/ajg.0000000000002536.


Patient perspectives on a proposed pharmacy-based colorectal cancer screening program.

Ferrari R, Atkins D, Wangen M, Rohweder C, Waters A, Correa S Transl Behav Med. 2023; 13(12):909-918.

PMID: 37756664 PMC: 10724111. DOI: 10.1093/tbm/ibad057.


Colorectal cancer screening preferences among physicians and individuals at average risk: A discrete choice experiment.

Heidenreich S, Finney Rutten L, Miller-Wilson L, Jimenez-Moreno C, Chua G, Fisher D Cancer Med. 2022; 11(16):3156-3167.

PMID: 35315224 PMC: 9385595. DOI: 10.1002/cam4.4678.

References
1.
Pickhardt P . Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection. Abdom Radiol (NY). 2016; 41(8):1441-4. PMC: 4974132. DOI: 10.1007/s00261-016-0798-4. View

2.
Qaseem A, Crandall C, Mustafa R, Hicks L, Wilt T, Forciea M . Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. Ann Intern Med. 2019; 171(9):643-654. PMC: 8152103. DOI: 10.7326/M19-0642. View

3.
Wolf A, Fontham E, Church T, Flowers C, Guerra C, LaMonte S . Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018; 68(4):250-281. DOI: 10.3322/caac.21457. View

4.
Maciosek M, Solberg L, Coffield A, Edwards N, Goodman M . Colorectal cancer screening: health impact and cost effectiveness. Am J Prev Med. 2006; 31(1):80-9. DOI: 10.1016/j.amepre.2006.03.009. View

5.
Johnson D, Barclay R, Mergener K, Weiss G, Konig T, Beck J . Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One. 2014; 9(6):e98238. PMC: 4046970. DOI: 10.1371/journal.pone.0098238. View